Preclinical reports advise that retatrutide may well affect obesity-connected cancer development. In the review led by Marathe et al., retatrutide-induced weight-loss reduced tumor engraftment, delayed tumor onset, and drastically attenuated tumor development in pancreatic and lung cancer products,